Meeting
2018 Gastrointestinal Cancers Symposium
Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab + first-line (1L) FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
Authors
Timothy Jay Price
Queen Elizabeth Hospital/ University of Adelaide, Adelaide, Australia
Timothy Jay Price , Lin Shen , Brigette Ma , Regina Esser , Wen-Feng Chen , Peter Gibbs , Robert S.C. Lim , Ann-Lii Cheng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT00778830
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 747)
DOI
10.1200/JCO.2018.36.4_suppl.747
Abstract #
747
Poster Bd #
J13
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
First Author: Timothy Jay Price
Poster
2015 Gastrointestinal Cancers Symposium
Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).
First Author: Ann-Lii Cheng
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Emergence of RAS mutations in RAS wild type metastatic colorectal cancer patients receiving cetuximab as first-line treatment: A prospective study.
First Author: Hsiang-Lin Tsai
Poster
2018 Gastrointestinal Cancers Symposium
Analysis of RAS/BRAF mutations in a randomized phase II WJOG6510G study of panitumumab plus irinotecan versus cetuximab plus irinotecan in chemorefractory metastatic colorectal cancer.
First Author: Tomohiro Nishina